107 related articles for article (PubMed ID: 16449680)
1. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling.
Le LP; Le HN; Dmitriev IP; Davydova JG; Gavrikova T; Yamamoto S; Curiel DT; Yamamoto M
J Natl Cancer Inst; 2006 Feb; 98(3):203-14. PubMed ID: 16449680
[TBL] [Abstract][Full Text] [Related]
2. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region.
Ono HA; Le LP; Davydova JG; Gavrikova T; Yamamoto M
Cancer Res; 2005 Nov; 65(22):10154-8. PubMed ID: 16287998
[TBL] [Abstract][Full Text] [Related]
4. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
5. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.
Douglas JT; Kim M; Sumerel LA; Carey DE; Curiel DT
Cancer Res; 2001 Feb; 61(3):813-7. PubMed ID: 11221860
[TBL] [Abstract][Full Text] [Related]
6. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
7. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
8. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
9. Replication-selective oncolytic viruses in the treatment of cancer.
Everts B; van der Poel HG
Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of adenoviral vectors by flow cytometry.
Weaver LS; Kadan MJ
Methods; 2000 Jul; 21(3):297-312. PubMed ID: 10873484
[TBL] [Abstract][Full Text] [Related]
11. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
Wang Y; Xue SA; Hallden G; Francis J; Yuan M; Griffin BE; Lemoine NR
Cancer Res; 2005 Feb; 65(4):1523-31. PubMed ID: 15735041
[TBL] [Abstract][Full Text] [Related]
12. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.
Kawakami Y; Li H; Lam JT; Krasnykh V; Curiel DT; Blackwell JL
Cancer Res; 2003 Mar; 63(6):1262-9. PubMed ID: 12649186
[TBL] [Abstract][Full Text] [Related]
13. Growth characteristics of human adenoviruses on porcine cell lines.
Griesche N; Zikos D; Witkowski P; Nitsche A; Ellerbrok H; Spiller OB; Pauli G; Biere B
Virology; 2008 Apr; 373(2):400-10. PubMed ID: 18191169
[TBL] [Abstract][Full Text] [Related]
14. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
Gomez-Manzano C; Balague C; Alemany R; Lemoine MG; Mitlianga P; Jiang H; Khan A; Alonso M; Lang FF; Conrad CA; Liu TJ; Bekele BN; Yung WK; Fueyo J
Oncogene; 2004 Mar; 23(10):1821-8. PubMed ID: 15014451
[TBL] [Abstract][Full Text] [Related]
15. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
[TBL] [Abstract][Full Text] [Related]
16. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
18. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.
Parikh NS; Currier MA; Mahller YY; Adams LC; Di Pasquale B; Collins MH; Cripe TP
Pediatr Blood Cancer; 2005 May; 44(5):469-78. PubMed ID: 15570577
[TBL] [Abstract][Full Text] [Related]
20. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
